BR0210869A - Compound, pharmaceutical composition, process of preparing a pharmaceutical composition, methods of treating an individual suffering from a disorder, depression and anxiety, obesity, overactive bladder and a disorder in an individual, reducing an individual's body mass and relieve urinary urge incontinence and the symptoms of a disorder in an individual - Google Patents
Compound, pharmaceutical composition, process of preparing a pharmaceutical composition, methods of treating an individual suffering from a disorder, depression and anxiety, obesity, overactive bladder and a disorder in an individual, reducing an individual's body mass and relieve urinary urge incontinence and the symptoms of a disorder in an individualInfo
- Publication number
- BR0210869A BR0210869A BR0210869-0A BR0210869A BR0210869A BR 0210869 A BR0210869 A BR 0210869A BR 0210869 A BR0210869 A BR 0210869A BR 0210869 A BR0210869 A BR 0210869A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- disorder
- pharmaceutical composition
- compound
- preparing
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO DE PREPARAR UMA COMPOSIçãO FARMACêUTICA, MéTODOS DE TRATAR UM INDIVìDUO QUE SOFRE DE UM DISTúRBIO, DE DEPRESSãO E DE ANSIEDADE, OBESIDADE, BEXIGA HIPERATIVA E UM DISTúRBIO EM UM INDIVìDUO, DE REDUZIR A MASSA CORPORAL DE UM INDIVìDUO E DE ALIVIAR INCONTINêNCIA DE URGêNCIA URINáRIA E OS SINTOMAS DE UM DISTúRBIO EM UM INDIVìDUO". A invenção refere-se a compostos que são antagonistas seletivos para receptores de hormónio concentrador de melanina (MCH1). A invenção proporciona uma composição farmacêutica compreendendo uma quantidade terapeuticamente efetiva do composto da invenção e um veículo farmaceuticamente aceitável. Esta invenção proporciona uma composição farmacêutica preparada combinando-se uma quantidade terapeuticamente efetiva do composto desta invenção e um veículo farmaceuticamente aceitável. Esta invenção proporciona adicionalmente um processo para preparar uma composição farmacêutica compreendendo combinar uma quantidade terapeuticamente efetiva do composto da invenção e um veículo farmaceuticamente aceitável."COMPOUND, PHARMACEUTICAL COMPOSITION, PROCESS OF PREPARING A PHARMACEUTICAL COMPOSITION, METHODS OF TREATING AN INDIVIDUAL SUFFERING FROM A DISORDER, DEPRESSION AND ANXIETY, OBESITY, HYDERATIVE BLADDER AND AN INDIVIDUAL DISTURAL BODY TO RELIEVE URINARY URGENCY INCONTINENCE AND THE SYMPTOMS OF A DISTURBANCE IN AN INDIVIDUAL ". The invention relates to compounds which are selective antagonists for melanin concentrating hormone (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition prepared by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for preparing a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89979401A | 2001-07-05 | 2001-07-05 | |
US4258201A | 2001-07-09 | 2001-07-09 | |
PCT/US2002/021063 WO2003004027A1 (en) | 2001-07-05 | 2002-07-03 | Substituted anilinic piperidines as mch selective antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0210869A true BR0210869A (en) | 2004-06-29 |
Family
ID=32599475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0210869-0A BR0210869A (en) | 2001-07-05 | 2002-07-03 | Compound, pharmaceutical composition, process of preparing a pharmaceutical composition, methods of treating an individual suffering from a disorder, depression and anxiety, obesity, overactive bladder and a disorder in an individual, reducing an individual's body mass and relieve urinary urge incontinence and the symptoms of a disorder in an individual |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR0210869A (en) |
-
2002
- 2002-07-03 BR BR0210869-0A patent/BR0210869A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312256A (en) | Compound, pharmaceutical composition, process for the preparation of a pharmaceutical composition, and method of treating an individual suffering from an mch1 receptor mediated disorder and treating an individual suffering from depression, anxiety, urge incontinence or obesity | |
BRPI0406725A (en) | Compound, pharmaceutical composition, process for preparing it, and methods for treating an individual suffering from an affective disorder, treating an individual suffering from an urinary disorder, and treating an individual suffering from an eating disorder | |
BR0010138A (en) | Glucocorticoid receptor modulators | |
MXPA02001306A (en) | Pharmaceutical compositions for the treatment of cns and other discorders. | |
WO2002060392A3 (en) | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
WO2002053177A3 (en) | Agents and methods for treating pain | |
UA49796C2 (en) | paroxetine hydrochloride anhydrate, method for preparing the above, paroxetine hydrochloride, method of preparing the above, method of treating and/or diseases preventing and pharmaceutical composition | |
ATE456953T1 (en) | TREATMENT OF AMYOTROPHIC LATERAL SCLERosis WITH PYRIMETHAMINE AND ANALOGS | |
CA2440605A1 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
BR0200246A (en) | Combination treatment for depression | |
BR0312257A (en) | Compound, pharmaceutical composition, process for the preparation thereof, and method of treating an individual suffering from an mch1 receptor mediated disorder, and an individual suffering from depression, anxiety, urinary incontinence, or obesity | |
EP1213031A3 (en) | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | |
TW200631956A (en) | Azabenzoxazoles for the treatment of CNS disorders | |
BR0104345A (en) | Combined treatment for depression and anxiety | |
BR0210869A (en) | Compound, pharmaceutical composition, process of preparing a pharmaceutical composition, methods of treating an individual suffering from a disorder, depression and anxiety, obesity, overactive bladder and a disorder in an individual, reducing an individual's body mass and relieve urinary urge incontinence and the symptoms of a disorder in an individual | |
MXPA05013104A (en) | Method for the treatment or prevention of lower urinary tract symptoms. | |
HUP0203050A2 (en) | Treating endometriosis or infertility, or improving fertility | |
BR9814867A (en) | Method for treating disease-related or drug-induced dyskinesias | |
UA85575C2 (en) | 4-aryl piperidines | |
WO2003043640A3 (en) | Treatment of major depressive disorder using glucocorticoid receptor antagonists | |
CA2671776A1 (en) | Gal3 receptor antagonists for the treatment of depression | |
WO2000004012A8 (en) | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | |
EP1159970A3 (en) | A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent | |
ATE545627T1 (en) | SMOOTH MUSCLE SPASMOLYTICS | |
WO2004034967A3 (en) | 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: H. LUNDBECK A/S (DK) Free format text: TRANSFERIDO DE: SYNAPTIC PHARMACEUTICAL CORPORATION |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |